# Contact Wolverine Compound: Editorial Corrections on BPC-157 TB-500 Coverage

> Contact Wolverine Compound about our BPC-157 TB-500 editorial coverage — corrections, citation questions, and feedback. We do not provide medical advice or supply any product.

Editorial feedback, corrections, and citation questions are welcome. Medical questions belong with a licensed professional, not with us.

## What to write to us about

This is the contact page for Wolverine Compound, the independent editorial digest of the BPC-157 TB-500 research record. The most useful messages are about the content itself: a citation that needs correcting, a study we should add, a number that looks off, or a place where the writing could be clearer. We read corrections seriously and update the record when a claim needs fixing, because a digest is only as good as the sources behind it.

The BPC-157 TB-500 literature moves in two directions at once — new component studies arrive, and the regulatory picture shifts, as with the scheduled July 2026 advisory-committee review. If you have spotted a newer peer-reviewed study, a more precise figure, or an FDA update we should reflect, that is exactly the kind of note that improves the site. Please include enough detail for us to verify it independently.

What we cannot do is give medical, clinical, or legal advice. We are not a clinic and not a prescriber, we do not employ clinicians, and we do not sell, supply, or source any peptide or the blend. For anything involving your own health, please speak with an appropriately licensed professional. Questions about buying or obtaining either peptide are outside what this editorial project does, and we will not be able to help with them.

## Send a message

Use the form below to reach the editorial team. Please include enough detail — the page, the claim, and the source if you have one — for us to act on a correction. We do not respond to requests to buy, sell, or source any substance, and we do not provide individual health guidance.

---

A pastel night-sketchbook of the BPC-157 and TB-500 record — each peptide doodled gently against its own studies, the untested combination left as a blank page, and the FDA 503A status drawn in before anything else; no clinic behind the notebook and nothing here dispensed or sold.